Research Topics
Species | Maha AyyoubSummaryAffiliation: Columbia University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patientsMaha Ayyoub
Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
Cancer Res 63:5601-6. 2003....- Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccineDanila Valmori
Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
Cancer Immun 3:15. 2003.... - Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1Maha Ayyoub
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, CH-1005 Lausanne, Switzerland
Clin Cancer Res 9:669-77. 2003..CONCLUSIONS: Patient immunization with the analog peptide leads to in vivo activation of T cells that were specific for the natural tumor antigen, demonstrating the usefulness of the analog peptide for melanoma immunotherapy... - Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responsesLaurence Chapatte
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
Cancer Res 66:5461-8. 2006..These results suggest that the inefficient processing of self-antigens, such as Melan-A, by the immunoproteasomes of professional antigen-presenting cells prevents the induction of antitumor T-cell responses in vivo... - Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanomaMaha Ayyoub
Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
J Immunol 168:1717-22. 2002.... - Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanomaPedro Romero
Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
Immunol Rev 188:81-96. 2002.... - Tinkering with nature: the tale of optimizing peptide based cancer vaccinesOlivier Michielin
Office of Information Technology, Ludwig Institute for Cancer Research, Epalinges, Switzerland
Cancer Treat Res 123:267-91. 2005 - Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificityVerena Rubio-Godoy
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital (CHUV, Lausanne, Switzerland
Eur J Immunol 32:2292-9. 2002..These results underline the high predictive value of positional scanning synthetic combinatorial peptide library analysis and encourage its use for the identification of CTL ligands... - A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patientsMaha Ayyoub
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Clin Immunol 118:188-94. 2006..We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens... - Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cellsDanila Valmori
Ludwig Institute Clinical Trial Center, Department of Medicine, Columbia University College of Physicians and Surgeons, Black Building 20 09, 650 West 168th Street, New York, NY 10032, USA
J Immunol 177:944-9. 2006..This condition, however, is temporary and reversible as it is dependent upon the continuous presence of rapamycin... - Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individualsDanila Valmori
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
Clin Immunol 117:161-7. 2005..In contrast, no reactivity was found against the amino-terminal part of the protein, which was concomitant with the paucity, in this region, of sequences with predicted high binding to MHC class II molecules... - A peripheral circulating compartment of natural naive CD4 TregsDanila Valmori
Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
J Clin Invest 115:1953-62. 2005..The definition of this subset has important implications for the analysis of human naturally occurring Tregs and for their targeting in therapeutic immune interventions... - Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responsesDanila Valmori
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Clin Immunol 117:24-30. 2005.... - Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigenDanila Valmori
Ludwig Institute Clinical Trial Center, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
Clin Immunol 122:163-72. 2007..Our results support the concept that epitope clustering within defined protein regions identifies tumor antigen immunodominant regions and suggest a general strategy for their identification... - Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?Danila Valmori
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York, USA
PLoS Med 1:e26. 2004 - CD4+ T cell responses to SSX-4 in melanoma patientsMaha Ayyoub
Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
J Immunol 174:5092-9. 2005.... - Lentivector immunization induces tumor antigen-specific B and T cell responses in vivoJavier Garcia Casado
Ludwig Institute for Cancer Research Lausanne Branch, University of Lausanne, Chemin des Boveresses 155, Epalinges, Switzerland
Eur J Immunol 38:1867-76. 2008..The induced CD4+ T cells were primarily directed against a single NY-ESO-1 epitope spanning amino acids 81-100. Altogether, our study shows that rLV/ESO induces potent and comprehensive immune responses in vivo... - Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-primingDanila Valmori
Ludwig Institute Clinical Trial Center, Columbia University, New York, NY 10032, USA
Proc Natl Acad Sci U S A 104:8947-52. 2007.... - Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individualsEmmanuelle Godefroy
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Cancer Immunol Immunother 56:1183-92. 2007.... - A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemiaDanila Valmori
Blood 101:4643-4. 2003 - Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsElke Jager
Ludwig Institute Clinical Trial Center, Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, Steinbacher Hohl 2 26, 60488 Frankfurt, Germany
Proc Natl Acad Sci U S A 103:14453-8. 2006..In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination... - Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin contentSheng-Wei Ye
Department of Colorectal Surgery, Peking University School of Oncology, Beijing Cancer Hospital, No. 52 Fu-cheng Road, Hai-Dian District, Beijing 100036, PR China
J Clin Immunol 26:447-56. 2006.... - Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancerPedro M S Alves
NCCR, Molecular Oncology, ISREC, Ch des Boveresses 155, 1066 Epalinges, Switzerland
Cancer Immunol Immunother 56:839-47. 2007..Finally, evidence of a naturally acquired CT antigen-specific CD8(+) T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses... - SSX antigens as tumor vaccine targets in human sarcomaMaha Ayyoub
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Cancer Immun 3:13. 2003..The results of this study indicate that SSX antigens are relevant targets for the development of vaccine-based immunotherapy of sarcoma and encourage the start of vaccination trials using SSX-derived immunogens in sarcoma patients... - Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II allelesEmmanuelle Godefroy
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
Clin Immunol 121:54-62. 2006..Identification of these epitopes will be instrumental for the evaluation of the immune response to Melan-A in cancer patients... - CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitroSimon Rothenfusser
Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Germany
Blood 103:2162-9. 2004..These results demonstrate distinct functional properties of CpG-A and CpG-B with regard to CD8 T cells... - Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cellsDanila Valmori
Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
Clin Cancer Res 12:398-404. 2006.... - An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DRMaha Ayyoub
Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
J Clin Invest 113:1225-33. 2004.... - Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cellsMaha Ayyoub
Ludwig Institute Clinical Trial Center and Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
J Immunol 172:7206-11. 2004..In contrast, it was efficiently presented by autologous dendritic cells, supporting the concept that processing by professional APC is the main pathway through which the CD4(+) T cell immunoresponse to tumor Ags occurs in vivo... - The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcomaMaha Ayyoub
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Cancer Immun 4:7. 2004..Together, these findings strongly support the implementation of CTA-based immunotherapy of sarcoma as a means to improve the efficacy of the standard therapy... - Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2Maha Ayyoub
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Clin Immunol 114:70-8. 2005..Retrieval of multiple overlapping epitopes in a defined region of SSX-2 protein suggests the presence of a "hot spot" for T cell recognition that may prove sufficient for the induction of immune responses... - Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancerPedro M S Alves
National Center of Competence in Research, Molecular Oncology, ISREC, Ch des Boveresses 155, 1066 Epalinges, Switzerland
Cancer Immun 8:11. 2008..Our data suggest that this sequence should be considered as a target of immunological interventions against colorectal cancer... - Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ TregsValeria Tosello
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Clin Immunol 126:291-302. 2008..Our data suggest that a division of labor between CM and EM Tregs ensures tolerance at lymphoid and peripheral locations including tumor sites...